Background: Hyperphosphorylated tau (pTau) in Alzheimer's disease (AD) brain tissue is a complex mix of multiple tau species that are variably phosphorylated on up to 55 epitopes. Emerging studies suggest that phosphorylation of specific epitopes may alter the role of tau. The role of specific pTau species can be explored through protein interaction ("interactome") studies. These provide knowledge about the role of individual pTau species and critical context for tau-focused biomarker and drug-discovery studies. The aim of this study was to analyse the interactome of pTau217, which biomarker studies suggest is one of the earliest accumulating tau species in AD.

Methods: pTau217 interactors were identified in fresh-frozen human brain tissue from 10 cases of advanced AD using affinity purification-mass spectrometry. Cases were balanced for ApoE ε3/ε3 and ε4/ε4 genotypes (n = 5 each) to explore if ApoE influences pTau protein interactions. Results were compared to our previous pTauS396/S404 interactome dataset generated using the same cases to determine if individual pTau species have different interactomes.

Results: 579 proteins were significantly enriched by pTau217 co-immunoprecipitation in comparison to control IgG (p < 0.05; fold change >1.5). Of these, 23 proteins were identified as bona fide pTau217 interactors (SAINT score > 0.65), including known pTau interactors SQSTM1 and ubiquitin. Phosphorylation analysis of tau enriched by pTau217 vs pTau396/S404 co-immunoprecipitation confirmed enrichment of a different pools of tau, with pTau217 displaying fewer phosphorylated epitopes, hinting that pTau217 may be an earlier generated species. Despite these differences, 15 bona fide pTau217 tau interactors also interacted with pTauS396/S404 suggesting close similarities in interactomes (Fisher's exact p = 2.3 × 10). Common interactors notably included five subunits of an E3 ubiquitin ligase not previously been linked to tau or AD. 46 and 28 pTau217 interactors were identified in ApoE ε3/ε3 and ApoE ε4/ε4 cases respectively and these significantly overlapped (16 common interactors; Fisher's exact p = 4.3 × 10).

Conclusions: pTau217 interacts with many similar proteins to pTauS396/S404. Our results highlight a strong interaction between multiple pTau species and a novel E3 ubiquitin ligase, which may have an important role in AD and potentially tau degradation.

Download full-text PDF

Source
http://dx.doi.org/10.1002/alz.090560DOI Listing

Publication Analysis

Top Keywords

ptau species
16
ptau217 interactors
12
ptau217
10
tau
9
brain tissue
8
tau species
8
phosphorylated epitopes
8
role tau
8
individual ptau
8
interactors identified
8

Similar Publications

Background: Hyperphosphorylated tau (pTau) in Alzheimer's disease (AD) brain tissue is a complex mix of multiple tau species that are variably phosphorylated on up to 55 epitopes. Emerging studies suggest that phosphorylation of specific epitopes may alter the role of tau. The role of specific pTau species can be explored through protein interaction ("interactome") studies.

View Article and Find Full Text PDF

Background: Large-scale unbiased proteomic profiling studies have identified a cluster of 31 proteins co-expressed with APP, which is termed the matrisome module 42 (M42). M42 is enriched in AD risk genes, including APOE, with mostly secreted proteins that bind heparin, collectively strongly correlate with the burden of brain pathology and cognitive trajectory, and localize to amyloid plaques in AD brain. For these reasons, M42 has been nominated as a novel therapeutic target for enabling drug discovery by our TREAT-AD Center.

View Article and Find Full Text PDF

Background: P-tau217 has emerged as a compelling alternative to long-established p-tau181 to accurately measure tau modifications in biofluids in response to brain Abeta and tau deposition in Alzheimer's disease (AD). Understanding the specificity and significance of p-tau217 changes over AD stages is critical to interpret its potential response to treatments against Abeta and tau aggregation.

Methods: We measured p-tau217 phosphorylation by mass spectrometry.

View Article and Find Full Text PDF

Basic Science and Pathogenesis.

Alzheimers Dement

December 2024

Department of Neurosurgery, Maxine Dunitz Neurosurgical Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.

Background: Alzheimer's disease (AD) is the foremost cause of global dementia, also characterized by retinal changes involving Aβ, hyperphosphorylated-tau (p-tau), neuronal degeneration, and tissue atrophy. Mitochondrial-driven reactive oxygen species (ROS) production, linked to synaptic dysfunction, is common to various neurodegenerative conditions, including AD. Despite synaptic dysfunction being an early predictor of cognitive decline in AD, its occurrence in the AD retina is unexplored.

View Article and Find Full Text PDF

Basic Science and Pathogenesis.

Alzheimers Dement

December 2024

Yale University, New Haven, CT, USA.

Background: Advances in Alzheimer's disease (AD) have revealed a novel fluid biomarker, tau phosphorylated at T217 (pT217-tau), in CSF and plasma, that predicts AD prior to cognitive deficits. Understanding the role of pT217-tau is important in assessing efficacy of novel treatments aimed at early-stage disease. However, it is unknown why pT217-tau is effective in predicting brain pathology, as little is known about early, soluble pT217-tau brain expression.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!